Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Leerink Partners Remains Sidelined on Agios Pharma (AGIO) - PT to $56
February 19, 2016 7:30 AM ESTLeerink Partners maintained a Market Perform rating on Agios Pharma (NASDAQ: AGIO), and cut the price target to $56.00 (from $62.00), following the company's 4Q earnings call. AGIO provided a number of incremental pipeline updates. Leerink sees the announced AG-348 and AG-519 data at EHA in June and... More
Agios Pharma (AGIO) Reports Q4 Loss of $1.08/Share
February 18, 2016 7:15 AM ESTAgios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.08), versus ($0.76) reported last year. Revenue for the quarter came in at $6.22 million, versus $14.64 million reported last year.
For earnings history and earnings-related data on Agios Pharma (AGIO) click here.
... More